NXY-059

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 35/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Intracerebral Hemorrhage

Conditions

Intracerebral Hemorrhage

Trial Timeline

Aug 1, 2004 → Jan 1, 2006

NCT ID

NCT00075959

About NXY-059

NXY-059 is a phase 2 stage product being developed by AstraZeneca for Intracerebral Hemorrhage. The current trial status is completed. This product is registered under clinical trial identifier NCT00075959. Target conditions include Intracerebral Hemorrhage.

What happened to similar drugs?

0 of 2 similar drugs in Intracerebral Hemorrhage were approved

Approved (0) Terminated (0) Active (2)

🔄Recombinant Factor VIIa + Biological/Vaccine: PlaceboNovo NordiskPhase 3

🔄Recombinant Activated Factor VII (rFVIIa) + PlaceboNovo NordiskPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (3)

NCT ID	Phase	Status	Start	Completion	Indication
NCT00075959	Phase 2	Completed	Aug 1, 2004	Jan 1, 2006	Intracerebral Hemorrhage
NCT00119626	Phase 3	Completed	Jun 1, 2003	Feb 1, 2005	Cerebral Stroke
NCT00061022	Phase 3	Completed	May 1, 2003	Sep 1, 2006	Cerebral Stroke

Competing Products

6 competing products in Intracerebral Hemorrhage

See all competitors

Product	Company	Stage	Hype Score
Edaravone Dexborneol + Placebo	Sun Pharmaceutical	Phase 2	31
Recombinant Factor VIIa + Biological/Vaccine: Placebo	Novo Nordisk	Phase 3	47
Recombinant Activated Factor VII (rFVIIa) + Placebo	Novo Nordisk	Phase 3	44
PF-05230907	Pfizer	Phase 1	21
CN-105	Tiantan Bio	Phase 2	28
Albumin + Placebo	Baxter	Phase 2	24